An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

Affiliation auteurs!!!! Error affiliation !!!!
TitreAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma
Type de publicationJournal Article
Year of Publication2018
AuteursSaiag P., Robert C., Grob J.J, Mortier L., Dereure O., Lebbe C., Mansard S., Grange F., Neidhardt E-M., Lesimple T., Machet L., Bedane C., Jeudy G., Aubin F., Dreno B., Szenik A., Denden A., Dutriaux C.
JournalANNALS OF ONCOLOGY
Volume29
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN0923-7534